STOCK TITAN

Faeth Therapeutics: Trails Edge reports 5.4% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Faeth Therapeutics, Inc. shares: Trails Edge Biotechnology Master Fund, LP, its investment manager Trails Edge Capital Partners, LP, and Chief Investment Officer Ortav Yehudai each reported beneficial ownership of 1,385,878 shares, or 5.4%, as of November 9, 2026. The shares are held directly by the Master Fund; the manager and Yehudai may be deemed beneficial owners through their investment and voting discretion. The percentage is based on 25,843,945 shares outstanding as of September 30, 2026.

Beneficial ownership 1,385,878 shares Held directly by Trails Edge Biotechnology Master Fund, LP and also attributed to its investment manager and the manager's Chief Investment Officer, as of November 9, 2026.
Percentage of class 5.4% Reported beneficial ownership as of November 9, 2026.
Shares outstanding 25,843,945 shares Faeth Therapeutics, Inc. common shares outstanding as of September 30, 2026; basis for the reported ownership percentage.
beneficially own regulatory
"may be deemed to beneficially own an aggregate of 1,385,878 shares"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
sole power to vote regulatory
"Sole power to vote or to direct the vote: 1,385,878"
sole power to dispose regulatory
"Sole power to dispose or to direct the disposition of: 1,385,878"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many FTH shares did Trails Edge report owning?

Trails Edge Biotechnology Master Fund, LP directly held 1,385,878 shares of Faeth Therapeutics, Inc. as of November 9, 2026. Trails Edge Capital Partners, LP and Ortav Yehudai also reported beneficial ownership of that same position.

What percentage of FTH did Trails Edge report owning?

The reported position represented 5.4% of Faeth Therapeutics, Inc.'s outstanding shares. The percentage was based on 25,843,945 shares outstanding as of September 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





81728A207

(CUSIP Number)
11/09/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4 for additional information.


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4 for additional information.


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4 for additional information.


SCHEDULE 13G



Trails Edge Capital Partners, LP
Signature:/s/ Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai
Name/Title:Ortav Yehudai / Chief Investment Officer of Trails Edge Capital Partners, LLC
Date:11/17/2026
Trails Edge Biotechnology Master Fund, LP
Signature:/s/ Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai
Name/Title:Ortav Yehudai / Chief Investment Officer of Trails Edge GP, LLC
Date:11/17/2026
Ortav Yehudai
Signature:/s/ Ortav Yehudai
Name/Title:Ortav Yehudai / Individual
Date:11/17/2026
Exhibit Information

Exhibit 1- Joint Filing Agreement

Keep reading